Single-cell multi-omics technologies and methods characterize cell states and activities by
simultaneously integrating various single-modality omics methods that profile the …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

Phenotypic plasticity has emerged as a major contributor to intra-tumoral heterogeneity and
treatment resistance in cancer. Increasing evidence shows that glioblastoma (GBM) cells …

Malignant brain tumours are complex ecosystems containing neoplastic and stromal
components that generate adaptive and evolutionarily driven aberrant tissues in the central …

Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-
resistant bacterial biofilms. Similar populations with comparable features have since been …

One of the current stumbling blocks in our fight against cancer is the development of
acquired resistance to therapy, which is attributable to approximately 90% of cancer-related …

Glioblastoma progression in its early stages remains poorly understood. Here, we transfer
PDGFB and genetic barcodes in mouse brain to initiate gliomagenesis and enable direct …

Heterogeneity describes the differences among cancer cells within and between tumors. It
refers to cancer cells describing variations in morphology, transcriptional profiles …

Tumors reprogram their metabolism to generate complex neoplastic ecosystems. Here, we
demonstrate that glioblastoma (GBM) stem cells (GSCs) display elevated activity of the …

Brain cancers carry bleak prognoses, with therapeutic advances hel** only a minority of
patients over the past decade. The brain tumour microenvironment (TME) is highly …